Mary E Abood

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3230649/publications.pdf

Version: 2024-02-01

112	6,580	53794	69250
papers	citations	45 h-index	77 g-index

112	112	112	5730
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB¹ receptors on peripheral sympathetic nerves. British Journal of Pharmacology, 1996, 118, 2023-2028.	5.4	305
2	3-(1â€²,1â€²-Dimethylbutyl)-1-deoxy-Î”8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorganic and Medicinal Chemistry, 1999, 7, 2905-2914.	3.0	280
3	Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands. Journal of Biological Chemistry, 2009, 284, 29817-29827.	3.4	240
4	Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug and Alcohol Dependence, 2000, 60, 133-140.	3.2	235
5	CB 1 and CB 2 Receptor Pharmacology. Advances in Pharmacology, 2017, 80, 169-206.	2.0	229
6	Neurobiology of marijuana abuse. Trends in Pharmacological Sciences, 1992, 13, 201-206.	8.7	207
7	An Aromatic Microdomain at the Cannabinoid CB1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region. Journal of Medicinal Chemistry, 2003, 46, 5139-5152.	6.4	189
8	Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, 126, 301-313.		189
9	The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 2010, 160, 480-498.	5.4	161
10	Synthesis and Pharmacology of a Very Potent Cannabinoid Lacking a Phenolic Hydroxyl with High Affinity for the CB2 Receptor. Journal of Medicinal Chemistry, 1996, 39, 3875-3877.	6.4	149
11	Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches. Journal of Biological Chemistry, 2004, 279, 48024-48037.	3.4	142
12	Cannabinoid receptors: nomenclature and pharmacological principles. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 4-15.	4.8	139
13	Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. European Journal of Pharmacology, 1999, 377, 117-125.	3.5	132
14	AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European Journal of Pharmacology, 2006, 542, 100-105.	3.5	132
15	Activation of <scp>GPR</scp>18 by cannabinoid compounds: a tale of biased agonism. British Journal of Pharmacology, 2014, 171, 3908-3917.	5.4	131
16	Targeting of the Orphan Receptor GPR35 by Pamoic Acid: A Potent Activator of Extracellular Signal-Regulated Kinase and Î²-Arrestin2 with Antinociceptive Activity. Molecular Pharmacology, 2010, 78, 560-568.	2.3	113
17	HIV-1 infection and alcohol abuse: Neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain, Behavior, and Immunity, 2011, 25, S61-S70.	4.1	111
18	CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvascular Research, 2009, 78, 86-94.	2.5	110

#	Article	IF	Citations
19	Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Letters, 2001, 309, 197-201.	2.1	109
20	The Two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13087-13092.	7.1	109
21	Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 33-39.	1.2	108
22	CB₁ Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity. Molecular Pharmacology, 2013, 83, 322-338.	2.3	107
23	Isolation and expression of a mouse CB1 cannabinoid receptor gene. Biochemical Pharmacology, 1997, 53, 207-214.	4.4	103
24	Two-pore channels provide insight into the evolution of voltage-gated Ca ²⁺ and Na ⁺ channels. Science Signaling, 2014, 7, ra109.	3.6	98
25	Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Research, 1996, 706, 13-20.	2.2	89
26	Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-Oncology, 2005, 74, 31-40.	2.9	86
27	(-)-7â€²-Isothiocyanato-11-hydroxy-1â€²,1â€²-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2005, 68, 1623-1635.	2.3	86
28	Intracellular Cannabinoid Type 1 (CB1) Receptors Are Activated by Anandamide. Journal of Biological Chemistry, 2011, 286, 29166-29174.	3.4	83
29	Development of behavioral tolerance to Î”9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacology Biochemistry and Behavior, 1993, 46, 575-579.	2.9	81
30	Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1Transmembrane Helix 7. Molecular Pharmacology, 2007, 71, 1512-1524.	2.3	79
31	Biarylpyrazole Inverse Agonists at the Cannabinoid CB1 Receptor:Â Importance of the C-3 Carboxamide Oxygen/Lysine3.28(192) Interaction. Journal of Medicinal Chemistry, 2006, 49, 5969-5987.	6.4	77
32	Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5875-5878.	2.2	75
33	The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55. Journal of NeuroImmune Pharmacology, 2012, 7, 856-865.	4.1	75
34	Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. European Journal of Neuroscience, 2008, 27, 572-579.	2.6	69
35	Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor. Journal of Biological Chemistry, 2014, 289, 5828-5845.	3.4	67
36	A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochemical Pharmacology, 2002, 63, 2121-2136.	4.4	63

#	Article	IF	Citations
37	Identification of the GPR55 Agonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. Biochemistry, 2011, 50, 5633-5647.	2.5	62
38	Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors. Journal of Medicinal Chemistry, 2000, 43, 3778-3785.	6.4	61
39	The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors:Â Insights Gained from (E)- and (Z)-Naphthylidene Indenes. Journal of Medicinal Chemistry, 1998, 41, 5177-5187.	6.4	60
40	Molecular Neurobiology of The Cannabinoid Receptor. International Review of Neurobiology, 1996, 39, 197-221.	2.0	59
41	Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. Biochemistry, 2013, 52, 9456-9469.	2.5	59
42	Helix 8 Leu in the CB1 Cannabinoid Receptor Contributes to Selective Signal Transduction Mechanisms. Journal of Biological Chemistry, 2007, 282, 25100-25113.	3.4	54
43	Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials. American Journal of Hospice and Palliative Medicine, 2010, 27, 347-356.	1.4	54
44	Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug and Alcohol Dependence, 1994, 36, 27-31.	3.2	53
45	Developmental expression of cannabinoid receptor mRNA. Developmental Brain Research, 1993, 76, 75-78.	1.7	52
46	CB1 Cannabinoid Receptor Signaling and Biased Signaling. Molecules, 2021, 26, 5413.	3.8	50
47	The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray. Molecular Pharmacology, 2015, 88, 265-272.	2.3	48
48	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. Journal of Medicinal Chemistry, 2014, 57, 8777-8791.	6.4	46
49	Differential Activation of Intracellular versus Plasmalemmal CB₂ Cannabinoid Receptors. Biochemistry, 2014, 53, 4990-4999.	2.5	46
50	Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP3-Evoked Ca2+ Signals through Sigma-1 Receptors. Cell Reports, 2019, 26, 330-337.e4.	6.4	45
51	Mechanisms of modulation of brain microvascular endothelial cells function by thrombin. Brain Research, 2017, 1657, 167-175.	2.2	44
52	GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sciences, 2013, 92, 453-457.	4.3	43
53	Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy. Biological Psychiatry, 2015, 78, 693-701.	1.3	41
54	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry, 2020, 63, 542-568.	6.4	40

#	Article	IF	Citations
55	Cocaine inhibits store-operated Ca2+ entry in brain microvascular endothelial cells: critical role for sigma-1 receptors. Biochemical Journal, 2016, 473, 1-5.	3.7	39
56	Cannabinoid receptor activation reduces TNFÎ±-Induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology, 2010, 58, 551-558.	4.1	37
57	Differential Activation of Cultured Neonatal Cardiomyocytes by Plasmalemmal Versus Intracellular G Protein-coupled Receptor 55. Journal of Biological Chemistry, 2013, 288, 22481-22492.	3.4	36
58	Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. Neuroscience, 2018, 377, 105-113.	2.3	31
59	Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?. Journal of Medicinal Chemistry, 2020, 63, 14216-14227.	6.4	31
60	Antisense oligodeoxynucleotides to the Îº-1 receptor block the antinociceptive effects of Î”9-THC in the spinal cord. Brain Research, 1995, 689, 157-158.	2.2	30
61	Mapping the Structural Requirements in the CB₁Cannabinoid Receptor Transmembrane Helix II for Signal Transduction. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 341-348.	2.5	29
62	G proteinâ€coupled estrogen receptorâ€mediated effects on cytosolic calcium and nanomechanics in brain microvascular endothelial cells. Journal of Neurochemistry, 2015, 133, 629-639.	3.9	28
63	Stereoselective Î¼- and Î´-opioid receptor-related antinociception and binding with (+)-thebaine. European Journal of Pharmacology, 1999, 365, 143-147.	3.5	26
64	Unique Analogues of Anandamide:Â Arachidonyl Ethers and Carbamates and Norarachidonyl Carbamates and Ureas. Journal of Medicinal Chemistry, 1999, 42, 1975-1981.	6.4	26
65	Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6894-6902.	2.9	26
66	Progress toward Understanding the Cannabinoid Receptor and Its Second Messenger Systems. Advances in Pharmacology, 1994, 25, 341-397.	2.0	24
67	N-arachidonoyl glycine, another endogenous agonist of GPR55. Biochemical and Biophysical Research Communications, 2017, 490, 1389-1393.	2.1	23
68	High-Level Expression of the Human CB2 Cannabinoid Receptor Using a Baculovirus System. Biochemical Pharmacology, 1998, 55, 1893-1905.	4.4	22
69	An investigation into the structural determinants of cannabinoid receptor ligand efficacy. British Journal of Pharmacology, 1999, 126, 1575-1584.	5.4	22
70	Regulation of both preproenkephalin mRNA and its derived opioids by haloperidol â€” a method for measurement of peptides and mRNA in the same tissue extract. Molecular Brain Research, 1990, 8, 243-248.	2.3	21
71	Isolation and developmental expression of a rat cDNA encoding a cysteine-rich zinc finger protein. Nucleic Acids Research, 1994, 22, 5477-5483.	14.5	21
72	Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. Biochemistry, 2017, 56, 473-486.	2.5	21

#	Article	IF	Citations
73	Expression of a cannabinoid receptor in baculo virus-infected insect cells. Biochemical Pharmacology, 1994, 48, 1231-1243.	4.4	20
74	Crucial Positively Charged Residues for Ligand Activation of the GPR35 Receptor. Journal of Biological Chemistry, 2014, 289, 3625-3638.	3.4	20
75	GPR55-mediated effects on brain microvascular endothelial cells and the bloodâ€“brain barrier. Neuroscience, 2019, 414, 88-98.	2.3	20
76	Mechanisms of activation of nucleus accumbens neurons by cocaine via sigma-1 receptorâ€“inositol 1,4,5-trisphosphateâ€“transient receptor potential canonical channel pathways. Cell Calcium, 2015, 58, 196-207.	2.4	19
77	Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chemistry and Physics of Lipids, 2011, 164, 131-143.	3.2	18
78	Novel Insights into CB₁ Cannabinoid Receptor Signaling: A Key Interaction Identified between the Extracellular-3 Loop and Transmembrane Helix 2. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 189-197.	2.5	18
79	CB₁ Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling. Cannabis and Cannabinoid Research, 2016, 1, 272-280.	2.9	18
80	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. Journal of Medicinal Chemistry, 2021, 64, 8104-8126.	6.4	18
81	Modification of opioid agonist binding by pertussis toxin. Brain Research, 1987, 417, 70-74.	2.2	17
82	Importance of the C-1 Substituent in Classical Cannabinoids to CB2Receptor Selectivity:Â Synthesis and Characterization of a Series ofO,2-Propano-Î”8-tetrahydrocannabinol Analogs. Journal of Medicinal Chemistry, 1997, 40, 3312-3318.	6.4	17
83	Role for C-Tail Residues in Delta Opioid Receptor Downregulation. DNA and Cell Biology, 2000, 19, 93-101.	1.9	16
84	Acute cocaine administration alters permeability of blood-brain barrier in freely-moving ratsâ€” Evidence using miniaturized fluorescence microscopy. Drug and Alcohol Dependence, 2020, 206, 107637.	3.2	16
85	Membrane fluidity and fatty acid composition of phospholipids in erythrocyte membranes of patients with huntington disease. Journal of Neuroscience Research, 1979, 4, 183-187.	2.9	14
86	Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorganic and Medicinal Chemistry, 2017, 25, 6427-6434.	3.0	14
87	GPR55 in the brain and chronic neuropathic pain. Behavioural Brain Research, 2021, 406, 113248.	2.2	14
88	Antinociceptive activity of chemical congeners of improgan: Optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology, 2006, 51, 447-456.	4.1	13
89	Allosteric Modulators: A Side Door. Journal of Medicinal Chemistry, 2016, 59, 42-43.	6.4	13
90	Modulation of cardiac vagal tone by bradykinin acting on nucleus ambiguus. Neuroscience, 2017, 365, 23-32.	2.3	13

#	Article	IF	Citations
91	Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology, 1999, 128, 684-688.	5.4	12
92	Significance of Cannabinoid CB1 Receptors in Improgan Antinociception. Journal of Pain, 2007, 8, 850-860.	1.4	12
93	Cannabinoid Cancer Biology and Prevention. Journal of the National Cancer Institute Monographs, 2021, 2021, 99-106.	2.1	11
94	Design, synthesis and biological evaluation of GPR55 agonists. Bioorganic and Medicinal Chemistry, 2017, 25, 4355-4367.	3.0	10
95	Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues. British Journal of Pharmacology, 2001, 132, 525-535.	5.4	9
96	HIV Tat excites D1 receptor-like expressing neurons from rat nucleus accumbens. Drug and Alcohol Dependence, 2017, 178, 7-14.	3.2	9
97	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
98	Evaluation of a series of N-alkyl benzomorphans in cell lines expressing transfected Î´- and Î¼-opioid receptors. Biochemical Pharmacology, 1995, 50, 851-859.	4.4	6
99	Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1827-1830.	2.2	6
100	Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion. Concussion, 2017, 2, CNC49.	1.0	6
101	Effects of VPAC1 activation in nucleus ambiguus neurons. Brain Research, 2017, 1657, 297-303.	2.2	4
102	Structure-activity relationships of benzothiazole GPR35 antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 612-615.	2.2	4
103	Protocols and Good Operating Practices in the Study of Cannabinoid Receptors. Methods in Enzymology, 2017, 593, 23-42.	1.0	4
104	The NPXXY Motif Regulates Î²-Arrestin Recruitment by the CB1 Cannabinoid Receptor. Cannabis and Cannabinoid Research, 2023, 8, 731-748.	2.9	4
105	Molecular Biology of Cannabinoid Receptors: Mutational Analyses of the CB Receptors. , 2009, , 203-234.		3
106	Functional interaction between HIV-gp120 and opioid system in the preoptic anterior hypothalamus. Drug and Alcohol Dependence, 2014, 134, 383-386.	3.2	2
107	Contribution of G Protein-Coupled Receptor 55 to Periaqueductal Gray-Mediated Antinociception in the Inflammatory Pain. Cannabis and Cannabinoid Research, 2022, 7, 274-278.	2.9	2
108	Endocannabinoids and Intracellular Signaling. , 2005, , .		1

#	Article	IF	Citations
109	Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors. Receptors, 2013, , 263-280.	0.2	1
110	Design, Synthesis, and Pharmacological Evaluation of Novel Quinolone Aryl Sulfonamide Derivatives as Potent GPR55 Antagonists. Proceedings (mdpi), 2019, 22, .	0.2	0
111	The Anabolic Role of Cannabinoid Receptor in Bone. FASEB Journal, 2010, 24, 638.5.	0.5	0
112	Current Cannabinoid Receptor Nomenclature and Pharmacological Principles. , 2013, , 25-54.		0